LOS ANGELES CAPITAL MANAGEMENT LLC

Position in MDGL — Madrigal Pharmaceuticals, Inc.

CIK 1177206 LOS ANGELES, CA

Position in MDGL

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$2,104,844

+$1,559,389 QoQ

Shares Held

3,920

+276.2% QoQ

Ownership

0.017%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#158

of 411 holders

Holding Since

Mar 2020

13 quarters on record

Voting authority Sole 60% Shared 0% None 40%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. MDGL ranks #23 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,104,844	3,920	+276.2%	Shares	Sole	2026-08-13
2026-03-31	$545,455	1,042	-81.4%	Shares	Sole	2026-05-08
2025-12-31	$3,262,851	5,603	+9.3%	Shares	Sole	2026-02-11
2025-09-30	$2,350,173	5,124	-0.5%	Shares	Sole	2025-10-20
2025-06-30	$1,558,293	5,149	+98.3%	Shares	Sole	2025-08-07
2025-03-31	$859,873	2,596	-5.7%	Shares	Sole	2025-05-05
2024-12-31	$849,184	2,752	+167.4%	Shares	Sole	2025-02-04
2023-03-31	$249,285	1,029	-83.6%	Shares	Sole	2023-05-04
2021-03-31	$732,232	6,260	-45.4%	Shares	Sole	2021-05-05
2020-12-31	$1,274,230	11,462	+1.1%	Shares	Sole	2021-03-10
2020-09-30	$1,346,042	11,337	-12.8%	Shares	Sole	2020-11-02
2020-06-30	$1,471,910	12,997	+2.0%	Shares	Sole	2020-08-05
2020-03-31	$850,655	12,742	—	Shares	Sole	2020-05-04
No filing history on record for this holder in this stock.